NorthWest Biotherapeutics Inc (NWBO)

[skitahoe]

Going from 5% to 13% survival at 5 years is certainly no failure, it's over 150% improvement in 5 year survival, that by itself would be worthy of approval, and actually far better than what's achieved with many approved products. A 10% to 20% improvement in OS has moved many a product to approval, we're better than 150%, but it's in a cancer that's among the deadliest. I frankly don't believe the regulators will ignore the benefits achieved with Poly-ICLC taking the survival to over 50%, but they'll permit it by adding them to a compendium list permitting use covered by insurance essentially from the time DCVax-L is approved.

Clearly you're also right, many others are benefitted by living longer than previously, but not over 5 years. I would love to see a K-M that showed every patient to enter the trial extended out to the present. I don't know, but believe we might find that some of the patients who were first to enter the trial are still alive today.

Gary